Ultrasound localization microscopy (ULM) has revolutionized microvascular imaging by breaking the acoustic diffraction limit. However, different ULM workflows depend heavily on distinct prior knowledge, such as the impulse response and empirical selection of parameters (e.g., the number of microbubbles (MBs) per frame M), or the consistency of training-test dataset in deep learning (DL)-based studies. We hereby propose a general ULM pipeline that reduces priors. Our approach leverages a DL model that simultaneously distills microbubble signals and reduces speckle from every frame without estimating the impulse response and M. Our method features an efficient channel attention vision transformer (ViT) and a progressive learning strategy, enabling it to learn global information through training on progressively increasing patch sizes. Ample synthetic data were generated using the k-Wave toolbox to simulate various MB patterns, thus overcoming the deficiency of labeled data. The ViT output was further processed by a standard radial symmetry method for sub-pixel localization. Our method performed well on model-unseen public datasets: one in silico dataset with ground truth and four in vivo datasets of mouse tumor, rat brain, rat brain bolus, and rat kidney. Our pipeline outperformed conventional ULM, achieving higher positive predictive values (precision in DL, 0.88-0.41 vs. 0.83-0.16) and improved accuracy (root-mean-square errors: 0.25-0.14 λ vs. 0.31-0.13 λ) across a range of signal-to-noise ratios from 60 dB to 10 dB. Our model could detect more vessels in diverse in vivo datasets while achieving comparable resolutions to the standard method. The proposed ViT-based model, seamlessly integrated with state-of-the-art downstream ULM steps, improved the overall ULM performance with no priors.

Positron Emission Tomography (PET) is an important clinical imaging tool but inevitably introduces radiation exposure to patients and healthcare providers. Reducing the tracer injection dose and eliminating the CT acquisition for attenuation correction can reduce the overall radiation dose, but often results in PET with high noise and bias. Thus, it is desirable to develop 3D methods to translate the non-attenuation-corrected low-dose PET (NAC-LDPET) into attenuation-corrected standard-dose PET (AC-SDPET). Recently, diffusion models have emerged as a new state-of-the-art deep learning method for image-to-image translation, better than traditional CNN-based methods. However, due to the high computation cost and memory burden, it is largely limited to 2D applications. To address these challenges, we developed a novel 2.5D Multi-view Averaging Diffusion Model (MADM) for 3D image-to-image translation with application on NAC-LDPET to AC-SDPET translation. Specifically, MADM employs separate diffusion models for axial, coronal, and sagittal views, whose outputs are averaged in each sampling step to ensure the 3D generation quality from multiple views. To accelerate the 3D sampling process, we also proposed a strategy to use the CNN-based 3D generation as a prior for the diffusion model. Our experimental results on human patient studies suggested that MADM can generate high-quality 3D translation images, outperforming previous CNN-based and Diffusion-based baseline methods. The code is available at https://github.com/tianqic/MADM.

As ultrasound (US) is the most accurate tool for assessing the thyroid nodule (TN) risk of malignancy (RoM), international societies have published various Thyroid Imaging and Reporting Data Systems (TIRADSs). With the recent advent of artificial intelligence (AI), clinicians and researchers should ask themselves how AI could interpret the terminology of the TIRADSs and whether or not AIs agree in the risk assessment of TNs. The study aim was to analyze the interobserver agreement (IOA) between AIs in assessing the RoM of TNs across various TIRADSs categories using a cases series created combining TIRADSs descriptors. ChatGPT, Google Gemini, and Claude were compared. ACR-TIRADS, EU-TIRADS, and K-TIRADS, were employed to evaluate the AI assessment. Multiple written scenarios for the three TIRADS were created, the cases were evaluated by the three AIs, and their assessments were analyzed and compared. The IOA was estimated by comparing the kappa (κ) values. Ninety scenarios were created. With ACR-TIRADS the IOA analysis gave κ = 0.58 between ChatGPT and Gemini, 0.53 between ChatGPT and Claude, and 0.90 between Gemini and Claude. With EU-TIRADS it was observed κ value = 0.73 between ChatGPT and Gemini, 0.62 between ChatGPT and Claude, and 0.72 between Gemini and Claude. With K-TIRADS it was found κ = 0.88 between ChatGPT and Gemini, 0.70 between ChatGPT and Claude, and 0.61 between Gemini and Claude. This study found that there were non-negligible variability between the three AIs. Clinicians and patients should be aware of these new findings.

Hepatocellular carcinoma (HCC) is an aggressive cancer with limited biomarkers for predicting immunotherapy response. Recent advancements in large language models (LLMs) like GPT-4, GPT-4o, and Gemini offer the potential for enhancing clinical decision-making through multimodal data analysis. However, their effectiveness in predicting immunotherapy response, especially compared to human experts, remains unclear. This study assessed the performance of GPT-4, GPT-4o, and Gemini in predicting immunotherapy response in unresectable HCC, compared to radiologists and oncologists of varying expertise. A retrospective analysis of 186 patients with unresectable HCC utilized multimodal data (clinical and CT images). LLMs were evaluated with zero-shot prompting and two strategies: the 'voting method' and the 'OR rule method' for improved sensitivity. Performance metrics included accuracy, sensitivity, area under the curve (AUC), and agreement across LLMs and physicians.GPT-4o, using the 'OR rule method,' achieved 65% accuracy and 47% sensitivity, comparable to intermediate physicians but lower than senior physicians (accuracy: 72%, p = 0.045; sensitivity: 70%, p < 0.0001). Gemini-GPT, combining GPT-4, GPT-4o, and Gemini, achieved an AUC of 0.69, similar to senior physicians (AUC: 0.72, p = 0.35), with 68% accuracy, outperforming junior and intermediate physicians while remaining comparable to senior physicians (p = 0.78). However, its sensitivity (58%) was lower than senior physicians (p = 0.0097). LLMs demonstrated higher inter-model agreement (κ = 0.59-0.70) than inter-physician agreement, especially among junior physicians (κ = 0.15). This study highlights the potential of LLMs, particularly Gemini-GPT, as valuable tools in predicting immunotherapy response for HCC.

To assess the agreement between lumbar disc degeneration (DD) grading by the convolutional neural network model SpineNet and radiologist's visual grading. In a 14-year follow-up MRI study involving 19 male volunteers, lumbar DD was assessed by SpineNet and two radiologists using the Pfirrmann classification at baseline (age 37) and after 14 years (age 51). Pfirrmann summary scores (PSS) were calculated by summing individual disc grades. The agreement between the first radiologist and SpineNet was analyzed, with the second radiologist's grading used for inter-observer agreement. Significant differences were observed in the Pfirrmann grades and PSS assigned by the radiologist and SpineNet at both time points. SpineNet assigned Pfirrmann grade 1 to several discs and grade 5 to more discs compared to the radiologists. The concordance correlation coefficients (CCC) of PSS between the radiologist and SpineNet were 0.54 (95% CI: 0.28 to 0.79) at baseline and 0.54 (0.27 to 0.80) at follow-up. The average kappa (κ) values of 0.74 (0.68 to 0.81) at baseline and 0.68 (0.58 to 0.77) at follow-up. CCC of PSS between the radiologists was 0.83 (0.69 to 0.97) at baseline and 0.78 (0.61 to 0.95) at follow-up, with κ values ranging from 0.73 to 0.96. We found fair to substantial agreement in DD grading between SpineNet and the radiologist, albeit with notable discrepancies. These findings indicate that AI-based systems like SpineNet hold promise as complementary tools in radiological evaluation, including in longitudinal studies, but emphasize the need for ongoing refinement of AI algorithms.

CBCT has become an essential tool in orthodontics, although its use must remain judicious and evidence-based. This study provides an updated analysis of international recommendations concerning the use of CBCT in orthodontics, with a particular focus on clinical indications, radiation dose reduction, and recent technological advancements. A systematic review of guidelines published between 2015 and 2025 was conducted following the PRISMA methodology. Inclusion criteria comprised official directives from recognized scientific societies and clinical studies evaluating low dose protocols in orthodontics. The analysis of the 19 retained recommendations reveals a consensus regarding the primary indications for CBCT in orthodontics, particularly for impacted teeth, skeletal anomalies, periodontal and upper airways assessment. Dose optimization and the integration of artificial intelligence emerge as major advancements, enabling significant radiation reduction while preserving diagnostic accuracy. The development of low dose protocols and advanced reconstruction algorithms presents promising perspectives for safer and more efficient imaging, increasingly replacing conventional 2D radiographic techniques. However, an international harmonization of recommendations for these new imaging sequences is imperative to standardize clinical practices and enhance patient radioprotection.

Information overload in electronic health records requires effective solutions to alleviate clinicians' administrative tasks. Automatically summarizing clinical text has gained significant attention with the rise of large language models. While individual studies show optimism, a structured overview of the research landscape is lacking. This study aims to present the current state of the art on clinical text summarization using large language models, evaluate the level of evidence in existing research and assess the applicability of performance findings in clinical settings. This scoping review complied with the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. Literature published between January 1, 2019, and June 18, 2024, was identified from 5 databases: PubMed, Embase, Web of Science, IEEE Xplore, and ACM Digital Library. Studies were excluded if they did not describe transformer-based models, did not focus on clinical text summarization, did not engage with free-text data, were not original research, were nonretrievable, were not peer-reviewed, or were not in English, French, Spanish, or German. Data related to study context and characteristics, scope of research, and evaluation methodologies were systematically collected and analyzed by 3 authors independently. A total of 30 original studies were included in the analysis. All used observational retrospective designs, mainly using real patient data (n=28, 93%). The research landscape demonstrated a narrow research focus, often centered on summarizing radiology reports (n=17, 57%), primarily involving data from the intensive care unit (n=15, 50%) of US-based institutions (n=19, 73%), in English (n=26, 87%). This focus aligned with the frequent reliance on the open-source Medical Information Mart for Intensive Care dataset (n=15, 50%). Summarization methodologies predominantly involved abstractive approaches (n=17, 57%) on single-document inputs (n=4, 13%) with unstructured data (n=13, 43%), yet reporting on methodological details remained inconsistent across studies. Model selection involved both open-source models (n=26, 87%) and proprietary models (n=7, 23%). Evaluation frameworks were highly heterogeneous. All studies conducted internal validation, but external validation (n=2, 7%), failure analysis (n=6, 20%), and patient safety risks analysis (n=1, 3%) were infrequent, and none reported bias assessment. Most studies used both automated metrics and human evaluation (n=16, 53%), while 10 (33%) used only automated metrics, and 4 (13%) only human evaluation. Key barriers hinder the translation of current research into trustworthy, clinically valid applications. Current research remains exploratory and limited in scope, with many applications yet to be explored. Performance assessments often lack reliability, and clinical impact evaluations are insufficient raising concerns about model utility, safety, fairness, and data privacy. Advancing the field requires more robust evaluation frameworks, a broader research scope, and a stronger focus on real-world applicability.

Biochemical recurrence (BCR) after radical prostatectomy exhibits heterogeneous prognostic implications. Recent advancements in imaging and biomarkers have high potential for personalizing care. Prostate-specific membrane antigen imaging (PSMA)-PET/CT has revolutionized the BCR management in prostate cancer by detecting microscopic lesions earlier than conventional staging, leading to improved cancer control outcomes and changes in treatment plans in approximately two-thirds of cases. Salvage radiotherapy, often combined with androgen deprivation therapy, remains the standard treatment for high-risk BCR postprostatectomy, with PSMA-PET/CT guiding treatment adjustments, such as the radiation field, and improving progression-free survival. Advancements in biomarkers, genomic classifiers, and artificial intelligence-based models have enhanced risk stratification and personalized treatment planning, resulting in both treatment intensification and de-escalation. While conventional risk grouping relying on Gleason score and PSA level and kinetics remain the foundation for BCR management, PSMA-PET/CT, novel biomarkers, and artificial intelligence may enable more personalized treatment strategies.

PCOS (Poly-Cystic Ovary Syndrome) is a multifaceted disorder that often affects the ovarian morphology of women of their reproductive age, resulting in the development of numerous cysts on the ovaries. Ultrasound imaging typically diagnoses PCOS, which helps clinicians assess the size, shape, and existence of cysts in the ovaries. Nevertheless, manual ultrasound image analysis is often challenging and time-consuming, resulting in inter-observer variability. To effectively treat PCOS and prevent its long-term effects, prompt and accurate diagnosis is crucial. In such cases, a prediction model based on deep learning can help physicians by streamlining the diagnosis procedure, reducing time and potential errors. This article proposes a novel integrated approach, QEI-SAM (Quality Enhanced Image - Segment Anything Model), for enhancing image quality and ovarian cyst segmentation for accurate prediction. GAN (Generative Adversarial Networks) and CNN (Convolutional Neural Networks) are the most recent cutting-edge innovations that have supported the system in attaining the expected result. The proposed QEI-SAM model used Enhanced Super Resolution Generative Adversarial Networks (ESRGAN) for image enhancement to increase the resolution, sharpening the edges and restoring the finer structure of the ultrasound ovary images and achieved a better SSIM of 0.938, PSNR value of 38.60 and LPIPS value of 0.0859. Then, it incorporates the Segment Anything Model (SAM) to segment ovarian cysts and achieve the highest Dice coefficient of 0.9501 and IoU score of 0.9050. Furthermore, Convolutional Neural Network - ResNet 50, ResNet 101, VGG 16, VGG 19, AlexNet and Inception v3 have been implemented to diagnose PCOS promptly. Finally, VGG 19 has achieved the highest accuracy of 99.31%.

We conducted a systematic review and meta-analysis to evaluate the performance of magnetic resonance imaging (MRI)-derived deep learning (DL) models in predicting 1p/19q codeletion status in glioma patients. The literature search was performed in four databases: PubMed, Web of Science, Embase, and Scopus. We included the studies that evaluated the performance of end-to-end DL models in predicting the status of glioma 1p/19q codeletion. The quality of the included studies was assessed by the Quality assessment of diagnostic accuracy studies-2 (QUADAS-2) METhodological RadiomICs Score (METRICS). We calculated diagnostic pooled estimates and heterogeneity was evaluated using I². Subgroup analysis and sensitivity analysis were conducted to explore sources of heterogeneity. Publication bias was evaluated by Deeks' funnel plots. Twenty studies were included in the systematic review. Only two studies had a low quality. A meta-analysis of the ten studies demonstrated a pooled sensitivity of 0.77 (95% CI: 0.63-0.87), a specificity of 0.85 (95% CI: 0.74-0.92), a positive diagnostic likelihood ratio (DLR) of 5.34 (95% CI: 2.88-9.89), a negative DLR of 0.26 (95% CI: 0.16-0.45), a diagnostic odds ratio of 20.24 (95% CI: 8.19-50.02), and an area under the curve of 0.89 (95% CI: 0.86-0.91). The subgroup analysis identified a significant difference between groups depending on the segmentation method used. DL models can predict glioma 1p/19q codeletion status with high accuracy and may enhance non-invasive tumor characterization and aid in the selection of optimal therapeutic strategies.